Qiaochu Zhu1, Zhongyu Zhou2,3, Dan Wei2,3, Yang Jiao2,3, Yangpu Zhang4, Xiaohui Tian1, Yan Wang1, Fu Dong1, Aiqun Song2,3. 1. Hubei University of Chinese Medicine. 2. Hubei Provincial Hospital of Chinese Medicine. 3. Hubei Province Academy of Traditional Chinese Medicine. 4. Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, China.
Abstract
BACKGROUND: Allergic rhinitis (AR) is one of the most common chronic disease of the nasal mucosa globally. Several clinical studies have shown that sanfu acupoint herbal patching (SAHP) has obvious advantages in treating AR. Therefore, the purpose of this systematic review is to evaluate the effectiveness and safety of SAHP for treating AR. METHOD: The following 9 electronic databases will be searched from January 2010 to October 2020: PubMed/Medline, Web of Science, Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP Database, WANFANG Database, China Biology Medicine disc. The selection of the studies and the extraction of the data are independently completed by 2 reviewers. The qualities of the studies are evaluated by Cochrane risk-of-bias tool. The main outcome of included studies is total effective rate. Secondary outcomes are Total Nasal Symptom Score, recurrence rate, Rhinitis Quality of Life Questionnaire, adverse events and laboratory indicators: serum immunoglobulin E (IgE). And the STATA 14.0 software will be implemented for data synthesis and meta-analysis. RESULTS: The review is ongoing, no results can be reported. CONCLUSIONS: The systematic review will provide a better option for patients to treat AR. REGISTRATION NUMBER: INPLASY2020100101.
BACKGROUND: Allergic rhinitis (AR) is one of the most common chronic disease of the nasal mucosa globally. Several clinical studies have shown that sanfu acupoint herbal patching (SAHP) has obvious advantages in treating AR. Therefore, the purpose of this systematic review is to evaluate the effectiveness and safety of SAHP for treating AR. METHOD: The following 9 electronic databases will be searched from January 2010 to October 2020: PubMed/Medline, Web of Science, Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP Database, WANFANG Database, China Biology Medicine disc. The selection of the studies and the extraction of the data are independently completed by 2 reviewers. The qualities of the studies are evaluated by Cochrane risk-of-bias tool. The main outcome of included studies is total effective rate. Secondary outcomes are Total Nasal Symptom Score, recurrence rate, Rhinitis Quality of Life Questionnaire, adverse events and laboratory indicators: serum immunoglobulin E (IgE). And the STATA 14.0 software will be implemented for data synthesis and meta-analysis. RESULTS: The review is ongoing, no results can be reported. CONCLUSIONS: The systematic review will provide a better option for patients to treat AR. REGISTRATION NUMBER: INPLASY2020100101.
Authors: Eli O Meltzer; Michael S Blaiss; Robert M Naclerio; Stuart W Stoloff; M Jennifer Derebery; Harold S Nelson; John M Boyle; Mark A Wingertzahn Journal: Allergy Asthma Proc Date: 2012-09-13 Impact factor: 2.587